The impact of national non-pharmaceutical interventions (‘lockdowns’) on the presentation of cancer patients

One of the most ignored aspects of the COVID-19 pandemic has been the impact of public health measures by governments on wider health and welfare. From March 2020, hospitals in the UK saw a dramatic reduction in patients with cancer presenting due to multifactorial reasons. The impact of the pandemi...

Full description

Saved in:
Bibliographic Details
Published inEcancermedicalscience Vol. 15; p. 1180
Main Authors Purushotham, Arnie, Roberts, Graham, Haire, Kate, Dodkins, Joanna, Harvey-Jones, Elizabeth, Han, Lu, Rigg, Anne, Twinn, Claire, Pramesh, Conjeevaram, Ranganathan, Priya, Sullivan, Richard, Aggarwal, Ajay
Format Journal Article
LanguageEnglish
Published England Cancer Intelligence 03.02.2021
Subjects
Online AccessGet full text
ISSN1754-6605
1754-6605
DOI10.3332/ecancer.2021.1180

Cover

Loading…
Abstract One of the most ignored aspects of the COVID-19 pandemic has been the impact of public health measures by governments on wider health and welfare. From March 2020, hospitals in the UK saw a dramatic reduction in patients with cancer presenting due to multifactorial reasons. The impact of the pandemic on patients with cancer in the South East London Cancer Alliance was studied. The specific aims were (1) to examine the reduction in cancer diagnoses during the first wave of the pandemic and (2) to examine the stage of diagnosis of patients with cancer presenting during the pandemic compared with that of patients presenting before the pandemic. There was an 18.2% reduction in new cancer diagnoses (an estimate of 987 cancers), when compared with 2019. This fall in cancer diagnoses was most marked in patients with prostate (51.4%), gynaecological (29.7%), breast (29.5%) and lung (23.4%) cancers. There was an overall 3.9% increase in advanced stage presentation (Stages 3 and 4), with an overall 6.8% increase in Stage 4 cancers during this period. The greatest shifts were seen in lung (increase of 6.3%, with an 11.2% increase in Stage 4 cancer alone) and colorectal (5.4%) cancers. For prostate cancer, there was an increase in 3.8% in those presenting with Stage 4 disease. For breast cancer, there was an 8% reduction in patients diagnosed with Stage 1 cancer with commensurate increases in the proportion of those with Stage 2 disease. The experiences in cancer are a salient warning that pandemic control measures and policy need to balance all health and welfare. Alternative strategies need to be adopted during further waves of the current and any future pandemic to ensure that patients with cancer are prioritised for diagnosis and treatment to prevent late-stage presentation and an increase in avoidable deaths.
AbstractList One of the most ignored aspects of the COVID-19 pandemic has been the impact of public health measures by governments on wider health and welfare. From March 2020, hospitals in the UK saw a dramatic reduction in patients with cancer presenting due to multifactorial reasons. The impact of the pandemic on patients with cancer in the South East London Cancer Alliance was studied. The specific aims were (1) to examine the reduction in cancer diagnoses during the first wave of the pandemic and (2) to examine the stage of diagnosis of patients with cancer presenting during the pandemic compared with that of patients presenting before the pandemic. There was an 18.2% reduction in new cancer diagnoses (an estimate of 987 cancers), when compared with 2019. This fall in cancer diagnoses was most marked in patients with prostate (51.4%), gynaecological (29.7%), breast (29.5%) and lung (23.4%) cancers. There was an overall 3.9% increase in advanced stage presentation (Stages 3 and 4), with an overall 6.8% increase in Stage 4 cancers during this period. The greatest shifts were seen in lung (increase of 6.3%, with an 11.2% increase in Stage 4 cancer alone) and colorectal (5.4%) cancers. For prostate cancer, there was an increase in 3.8% in those presenting with Stage 4 disease. For breast cancer, there was an 8% reduction in patients diagnosed with Stage 1 cancer with commensurate increases in the proportion of those with Stage 2 disease. The experiences in cancer are a salient warning that pandemic control measures and policy need to balance all health and welfare. Alternative strategies need to be adopted during further waves of the current and any future pandemic to ensure that patients with cancer are prioritised for diagnosis and treatment to prevent late-stage presentation and an increase in avoidable deaths.
One of the most ignored aspects of the COVID-19 pandemic has been the impact of public health measures by governments on wider health and welfare. From March 2020, hospitals in the UK saw a dramatic reduction in patients with cancer presenting due to multifactorial reasons. The impact of the pandemic on patients with cancer in the South East London Cancer Alliance was studied. The specific aims were (1) to examine the reduction in cancer diagnoses during the first wave of the pandemic and (2) to examine the stage of diagnosis of patients with cancer presenting during the pandemic compared with that of patients presenting before the pandemic. There was an 18.2% reduction in new cancer diagnoses (an estimate of 987 cancers), when compared with 2019. This fall in cancer diagnoses was most marked in patients with prostate (51.4%), gynaecological (29.7%), breast (29.5%) and lung (23.4%) cancers. There was an overall 3.9% increase in advanced stage presentation (Stages 3 and 4), with an overall 6.8% increase in Stage 4 cancers during this period. The greatest shifts were seen in lung (increase of 6.3%, with an 11.2% increase in Stage 4 cancer alone) and colorectal (5.4%) cancers. For prostate cancer, there was an increase in 3.8% in those presenting with Stage 4 disease. For breast cancer, there was an 8% reduction in patients diagnosed with Stage 1 cancer with commensurate increases in the proportion of those with Stage 2 disease. The experiences in cancer are a salient warning that pandemic control measures and policy need to balance all health and welfare. Alternative strategies need to be adopted during further waves of the current and any future pandemic to ensure that patients with cancer are prioritised for diagnosis and treatment to prevent late-stage presentation and an increase in avoidable deaths.One of the most ignored aspects of the COVID-19 pandemic has been the impact of public health measures by governments on wider health and welfare. From March 2020, hospitals in the UK saw a dramatic reduction in patients with cancer presenting due to multifactorial reasons. The impact of the pandemic on patients with cancer in the South East London Cancer Alliance was studied. The specific aims were (1) to examine the reduction in cancer diagnoses during the first wave of the pandemic and (2) to examine the stage of diagnosis of patients with cancer presenting during the pandemic compared with that of patients presenting before the pandemic. There was an 18.2% reduction in new cancer diagnoses (an estimate of 987 cancers), when compared with 2019. This fall in cancer diagnoses was most marked in patients with prostate (51.4%), gynaecological (29.7%), breast (29.5%) and lung (23.4%) cancers. There was an overall 3.9% increase in advanced stage presentation (Stages 3 and 4), with an overall 6.8% increase in Stage 4 cancers during this period. The greatest shifts were seen in lung (increase of 6.3%, with an 11.2% increase in Stage 4 cancer alone) and colorectal (5.4%) cancers. For prostate cancer, there was an increase in 3.8% in those presenting with Stage 4 disease. For breast cancer, there was an 8% reduction in patients diagnosed with Stage 1 cancer with commensurate increases in the proportion of those with Stage 2 disease. The experiences in cancer are a salient warning that pandemic control measures and policy need to balance all health and welfare. Alternative strategies need to be adopted during further waves of the current and any future pandemic to ensure that patients with cancer are prioritised for diagnosis and treatment to prevent late-stage presentation and an increase in avoidable deaths.
One of the most ignored aspects of the COVID-19 pandemic has been the impact of public health measures by governments on wider health and welfare. From March 2020, hospitals in the UK saw a dramatic reduction in patients with cancer presenting due to multifactorial reasons. The impact of the pandemic on patients with cancer in the South East London Cancer Alliance was studied. The specific aims were (1) to examine the reduction in cancer diagnoses during the first wave of the pandemic and (2) to examine the stage of diagnosis of patients with cancer presenting during the pandemic compared with that of patients presenting before the pandemic. There was an 18.2% reduction in new cancer diagnoses (an estimate of 987 cancers), when compared with 2019. This fall in cancer diagnoses was most marked in patients with prostate (51.4%), gynaecological (29.7%), breast (29.5%) and lung (23.4%) cancers. There was an overall 3.9% increase in advanced stage presentation (Stages 3 and 4), with an overall 6.8% increase in Stage 4 cancers during this period. The greatest shifts were seen in lung (increase of 6.3%, with an 11.2% increase in Stage 4 cancer alone) and colorectal (5.4%) cancers. For prostate cancer, there was an increase in 3.8% in those presenting with Stage 4 disease. For breast cancer, there was an 8% reduction in patients diagnosed with Stage 1 cancer with commensurate increases in the proportion of those with Stage 2 disease. The experiences in cancer are a salient warning that pandemic control measures and policy need to balance all health and welfare. Alternative strategies need to be adopted during further waves of the current and any future pandemic to ensure that patients with cancer are prioritised for diagnosis and treatment to prevent late-stage presentation and an increase in avoidable deaths.
Author Haire, Kate
Aggarwal, Ajay
Dodkins, Joanna
Rigg, Anne
Roberts, Graham
Purushotham, Arnie
Harvey-Jones, Elizabeth
Sullivan, Richard
Han, Lu
Twinn, Claire
Pramesh, Conjeevaram
Ranganathan, Priya
Author_xml – sequence: 1
  givenname: Arnie
  surname: Purushotham
  fullname: Purushotham, Arnie
– sequence: 2
  givenname: Graham
  surname: Roberts
  fullname: Roberts, Graham
– sequence: 3
  givenname: Kate
  surname: Haire
  fullname: Haire, Kate
– sequence: 4
  givenname: Joanna
  surname: Dodkins
  fullname: Dodkins, Joanna
– sequence: 5
  givenname: Elizabeth
  surname: Harvey-Jones
  fullname: Harvey-Jones, Elizabeth
– sequence: 6
  givenname: Lu
  surname: Han
  fullname: Han, Lu
– sequence: 7
  givenname: Anne
  surname: Rigg
  fullname: Rigg, Anne
– sequence: 8
  givenname: Claire
  surname: Twinn
  fullname: Twinn, Claire
– sequence: 9
  givenname: Conjeevaram
  surname: Pramesh
  fullname: Pramesh, Conjeevaram
– sequence: 10
  givenname: Priya
  surname: Ranganathan
  fullname: Ranganathan, Priya
– sequence: 11
  givenname: Richard
  surname: Sullivan
  fullname: Sullivan, Richard
– sequence: 12
  givenname: Ajay
  surname: Aggarwal
  fullname: Aggarwal, Ajay
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33777173$$D View this record in MEDLINE/PubMed
BookMark eNp1kctKxDAYhYMo3h_AjXSpi465NE27EUS8geBG1yHNxYm2SU06ijsfQ1_PJzF1RlHBVcKfc74T_rMBlp13GoAdBCeEEHygpXBShwmGGE0QquASWEeMFnlZQrr8474GNmK8g7BENaarYI0QxhhiZB3011Od2a4Xcsi8yZwYrHeizVJS3k9F6ITUs8HKNLJu0OFRu1ERs733l9fWy3vln1x8f3nbz7zLhgTrg45J9AkakfM_Zn0apHHcAitGtFFvL85NcHN6cn18nl9enV0cH13mktT1kDOqKgVxiSQkVDOJK8OQokWFG2NqaZQpdIFgVVOklGhK0yhYNbJiqqQUU0I2weGc28-aTiuZsoNoeR9sJ8Iz98Ly3y_OTvmtf-SsrlhR4wTYWwCCf5jpOPDORqnbVjjtZ5FjCksKaQ3HrN2fWd8hX2tOAjYXyOBjDNpwaecbStG25QjysVC-KJSPhfKx0OREf5xf8P89H96Wqq8
CitedBy_id crossref_primary_10_1016_j_jtocrr_2023_100560
crossref_primary_10_1038_s41416_024_02703_w
crossref_primary_10_1111_bju_15699
crossref_primary_10_1089_hs_2021_0084
crossref_primary_10_1111_bju_16305
crossref_primary_10_1016_j_ciresp_2022_02_001
crossref_primary_10_1038_s41416_024_02931_0
crossref_primary_10_1016_j_ijdrr_2024_105140
crossref_primary_10_1038_s41416_024_02596_9
crossref_primary_10_1136_bmjonc_2022_000012
crossref_primary_10_1016_j_cireng_2022_02_017
crossref_primary_10_2478_inmed_2024_0274
crossref_primary_10_3390_cancers15041273
crossref_primary_10_1038_s41416_022_01909_0
crossref_primary_10_3390_cancers14020266
crossref_primary_10_1016_j_ejca_2021_04_019
crossref_primary_10_6004_jnccn_2021_7114
crossref_primary_10_2217_fon_2021_1329
crossref_primary_10_1016_S1470_2045_22_00754_9
crossref_primary_10_3390_cancers15194700
crossref_primary_10_3389_fpubh_2022_988736
crossref_primary_10_1038_s41416_022_01830_6
crossref_primary_10_1186_s12885_023_11795_1
crossref_primary_10_1007_s00520_023_07944_8
crossref_primary_10_1136_spcare_2023_004310
crossref_primary_10_1136_bmjopen_2021_059374
crossref_primary_10_1186_s12913_022_08166_0
crossref_primary_10_3390_ijerph182413269
crossref_primary_10_3390_ijerph20075223
crossref_primary_10_1016_S1470_2045_23_00511_9
crossref_primary_10_1007_s12029_021_00752_5
crossref_primary_10_3389_fonc_2023_998940
ContentType Journal Article
Copyright the authors; licensee ecancermedicalscience.
the authors; licensee cancermedicalscience. 2021
Copyright_xml – notice: the authors; licensee ecancermedicalscience.
– notice: the authors; licensee cancermedicalscience. 2021
DBID AAYXX
CITATION
NPM
7X8
5PM
DOI 10.3332/ecancer.2021.1180
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1754-6605
ExternalDocumentID PMC7987492
33777173
10_3332_ecancer_2021_1180
Genre Journal Article
GrantInformation_xml – fundername: Department of Health
  grantid: NIHR300599
GroupedDBID ---
29G
2WC
53G
5GY
5VS
7X7
8FI
8FJ
AAYXX
ABDBF
ABUWG
ACUHS
ADBBV
ADRAZ
AEGXH
AFKRA
AHMBA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
CCPQU
CITATION
CS3
DIK
EBD
EBS
EJD
ESX
FRP
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
KQ8
M48
M~E
OK1
OVT
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RNS
RPM
TR2
TUS
UKHRP
C1A
NPM
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c399t-75d8d0261c035e7c28f71d5482bff9cfdf4e4108951ddab6fbd08bc87d6552533
IEDL.DBID M48
ISSN 1754-6605
IngestDate Thu Aug 21 14:00:48 EDT 2025
Fri Sep 05 09:10:03 EDT 2025
Mon Jul 21 06:00:02 EDT 2025
Tue Jul 01 02:44:24 EDT 2025
Thu Apr 24 23:02:56 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords COVID-19
diagnosis
cancer
stage
pandemic
shift
Language English
License the authors; licensee ecancermedicalscience.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c399t-75d8d0261c035e7c28f71d5482bff9cfdf4e4108951ddab6fbd08bc87d6552533
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.3332/ecancer.2021.1180
PMID 33777173
PQID 2506505903
PQPubID 23479
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7987492
proquest_miscellaneous_2506505903
pubmed_primary_33777173
crossref_citationtrail_10_3332_ecancer_2021_1180
crossref_primary_10_3332_ecancer_2021_1180
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-02-03
PublicationDateYYYYMMDD 2021-02-03
PublicationDate_xml – month: 02
  year: 2021
  text: 2021-02-03
  day: 03
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Ecancermedicalscience
PublicationTitleAlternate Ecancermedicalscience
PublicationYear 2021
Publisher Cancer Intelligence
Publisher_xml – name: Cancer Intelligence
SSID ssj0061925
Score 2.337953
Snippet One of the most ignored aspects of the COVID-19 pandemic has been the impact of public health measures by governments on wider health and welfare. From March...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1180
Title The impact of national non-pharmaceutical interventions (‘lockdowns’) on the presentation of cancer patients
URI https://www.ncbi.nlm.nih.gov/pubmed/33777173
https://www.proquest.com/docview/2506505903
https://pubmed.ncbi.nlm.nih.gov/PMC7987492
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9tAEB7iGIwvIX0racwWemgLcvVa7epQQltsTMGmlBp8E9I-SGiQndiB5Jafkf69_JLO6OHaremhZ-0sq_12mW9mdmYAXkuRGal87drcGDfSkruZNcqVPM44N4HgZYb3eBKPptGXGZ_tQdPeqt7A5U7TjvpJTa8u-jeXt6d44T-QxRmGwXujaIOouGfg96mkWQvaqJhiOuTjaB1UIFOBV4HN3WJd6IShEBSX3tZSf1HPP19Qbqik4SEc1FySfazAfwR7pngMnXEdLX8CCzwDrEqDZHPLGr8fQ4vfXZxt-rLZ-cbTxyV783B3j0ruhybX88Pdz7dsXjBkimzxO1mpoCmrf2N1cdblU5gOB98_j9y6w4KrkJisXMG11GSFKS_kRqhAWuFrNGKC3NpEWW0jE_meRBqmdZbHNteezJUUOuY8QKb4DPZxzeYF5X4HHEUocIgUTJvMUPAm8qVNDGX_OuA1O5qquvw4dcG4SNEMITzSGo-U8EgJDwferUUWVe2Nfw1-1cCU4g2hsEdWmPn1MkWShzSUJ17owPMKtvV0Dd4OiC1A1wOo-vb2l-L8rKzCLRIpoiQ4-m_JY-jS6ssn4OFL2F9dXZsTZDirvActMRM9aH8aTL5-65V-gl55ln8B2PoFZQ
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+impact+of+national+non-pharmaceutical+interventions+%28%E2%80%98lockdowns%E2%80%99%29+on+the+presentation+of+cancer+patients&rft.jtitle=Ecancermedicalscience&rft.au=Purushotham%2C+Arnie&rft.au=Roberts%2C+Graham&rft.au=Haire%2C+Kate&rft.au=Dodkins%2C+Joanna&rft.date=2021-02-03&rft.pub=Cancer+Intelligence&rft.eissn=1754-6605&rft.volume=15&rft_id=info:doi/10.3332%2Fecancer.2021.1180&rft_id=info%3Apmid%2F33777173&rft.externalDocID=PMC7987492
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1754-6605&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1754-6605&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1754-6605&client=summon